Table 1 Baseline Characteristics Among the 4 Groups Divided by DD Quartiles
Variables | Q1 (n = 141) (< 0.38) | Q2 (n = 140) (0.38–0.67) | Q3 (n = 135) (0.68–1.03) | Q4 (n = 134) (> 1.03) | p |
|---|---|---|---|---|---|
Demographics | |||||
 Age, years | 59.79 ± 11.54 | 61.48 ± 12.46 | 64.51 ± 11.17 | 68.48 ± 11.68 | < 0.0001 |
 Age > 75 years, n (%) | 9 (6.4%) | 16 (11.4%) | 25 (18.5%) | 45 (33.6%) | < 0.0001 |
 Sex, female, n (%) | 10 (7.1%) | 14 (10.0%) | 22 (16.3%) | 21 (15.7%) | 0.053 |
 Systolic blood pressure,mmHg | 122.39 ± 23.44 | 123.73 ± 22.25 | 121.80 ± 22.66 | 116.52 ± 23.86 | 0.123 |
 Diastolic blood pressure,mmHg | 74.84 ± 17.49 | 75.10 ± 15.98 | 72.89 ± 16.38 | 68.37 ± 15.56 | 0.012 |
 Heart rate,bpm | 77.06 ± 12.07 | 79.16 ± 14.85 | 77.92 ± 15.47 | 77.98 ± 16.23 | 0.795 |
Medical history | |||||
 Previous PCI, n (%) | 3 (2.1%) | 5 (3.6%) | 5 (3.7%) | 5 (3.7%) | 0.851 |
 Smoker, n (%) | 85 (60.3%) | 86 (61.4%) | 76 (56.3%) | 79 (59.0%) | 0.842 |
 Diabetes, n (%) | 35 (24.8%) | 30 (21.4%) | 35 (25.9%) | 40 (29.9%) | 0.456 |
 Hypertension, n (%) | 78 (55.3%) | 81 (57.9%) | 79 (58.5%) | 82 (61.2%) | 0.804 |
 Anemia, n (%) | 26 (18.4%) | 36 (25.7%) | 33 (24.4%) | 55 (41.0%) | < 0.0001 |
 Prior MI, n(%) | 3 (2.1%) | 3 (2.1%) | 4 (3.0%) | 1 (0.7%) | 0.628 |
Laboratory measurements | |||||
 Serum creatinine, mg/dl | 0.82 ± 0.18 | 0.82 ± 0.19 | 0.86 ± 0.30 | 1.00 ± 0.41 | < 0.0001 |
 Serum creatinine > 1.5 mg/dl, n | 0 (0.0%) | 0 (0.0%) | 6 (4.4%) | 13 (9.7%) | < 0.0001 |
 eGFR<60 mL/min/1.73m2, n(%) | 3 (2.1%) | 3 (2.1%) | 13 (9.6%) | 23 (17.2%) | < 0.0001 |
 Hemoglobin, g/L | 143.04 ± 13.28 | 141.66 ± 15.08 | 140.81 ± 14.76 | 136.04 ± 19.99 | 0.002 |
 Hematocrit | 0.41 ± 0.04 | 0.41 ± 0.04 | 0.41 ± 0.04 | 0.40 ± 0.06 | 0.008 |
 Cholesterol, mmol/L | 5.00 ± 1.08 | 4.95 ± 1.24 | 4.75 ± 1.09 | 4.58 ± 1.10 | 0.007 |
 LDL-C, mmol/L | 3.40 ± 0.99 | 3.39 ± 1.06 | 3.21 ± 0.98 | 3.02 ± 1.00 | 0.007 |
 Triglycerides, mmol/L | 1.70 ± 1.25 | 1.48 ± 1.01 | 1.39 ± 0.93 | 1.44 ± 1.33 | 0.103 |
 LgNT-pro-BNP, pg/mL | 2.26 ± 0.60 | 2.26 ± 0.63 | 2.40 ± 0.59 | 2.60 ± 0.75 | < 0.0001 |
 Fibrinogen, g/L | 3.44 ± 0.75 | 3.51 ± 0.97 | 3.52 ± 0.92 | 3.78 ± 1.06 | 0.020 |
 INR | 1.08 ± 0.10 | 1.09 ± 0.10 | 1.15 ± 0.30 | 1.16 ± 0.14 | < 0.0001 |
 DD,ug/ml | 0.25 ± 0.08 | 0.52 ± 0.09 | 0.85 ± 0.10 | 1.71 ± 1.42 | < 0.0001 |
 LVEF | 56.17 ± 7.57 | 54.08 ± 7.31 | 53.91 ± 7.24 | 49.63 ± 9.67 | < 0.0001 |
 LVEF < 0.45, n(%) | 9 (6.4%) | 17 (12.1%) | 17 (12.6%) | 42 (31.3%) | < 0.0001 |
Medication | |||||
 Statin use, n (%) | 140 (99.3%) | 140 (100.0%) | 135 (100.0%) | 132 (98.5%) | 0.285 |
 Antiplatelet agents use, n (%) | 141 (100.0%) | 140 (100.0%) | 135 (100%) | 132 (98.5%) | 0.101 |
Procedural characteristic | |||||
 Perioperative IABP, n (%) | 0 (0.0%) | 2 (1.4%) | 3 (2.2%) | 8 (6.0%) | 0.009 |
 Perioperative hypotension, n (%) | 47 (33.3%) | 42 (30.0%) | 49 (36.3%) | 62 (46.3%) | 0.034 |
 Contrast volume, ml | 167.80 ± 53.57 | 181.79 ± 50.74 | 187.19 ± 51.93 | 189.18 ± 53.76 | 0.003 |
 Contrast volume ≥ 150 ml, n (%) | 79 (56.0%) | 100 (71.4%) | 100 (74.1%) | 103 (76.9%) | 0.001 |
 Number of stents | 1.34 ± 0.54 | 1.33 ± 0.55 | 1.33 ± 0.52 | 1.18 ± 0.42 | 0.116 |
 Number of diseased vessels, n | 2.16 ± 0.90 | 2.18 ± 0.86 | 2.41 ± 0.81 | 2.23 ± 0.83 | 0.147 |
 Stent length,mm | 36.62 ± 17.54 | 35.10 ± 17.52 | 36.92 ± 18.39 | 31.75 ± 12.17 | 0.134 |
Merhan risk score | 7.50 ± 4.99 | 8.04 ± 4.50 | 8.97 ± 5.48 | 11.64 ± 5.79 | < 0.0001 |
Vascular access | Â | Â | Â | Â | 0.622 |
 Radial access | 125 (88.7%) | 120 (85.7%) | 121 (89.6%) | 117 (87.3%) |  |
 Femoral accessra | 16 (11.3%) | 17 (12.2%) | 11 (8.2%) | 14 (10.5%) |  |
 Radial access + femoral access | 0 (0.0%) | 3 (2.1%) | 3 (2.2%) | 3 (2.2%) |  |